Interact with industry partners and JAX scientists on the latest trends in oncology and immuno-oncology research and drug development.
Symposium dates and locations are:
- Cambridge, UK on October 8th
- Paris, France on October 10th
- Zurich, Switzerland on October 12th
- Heidelberg, Germany on October 15th
Time
-10:00 - 11:00: Registration
-11:00 - 12:45: Presentations
-12:45 - 13:45: Lunch
-14:00 - 15:45: Presentations
-15:45 - 16:15: Closing Remarks
Details for each location are below. Please fill out the form to register for the upcoming symposium you'd like to attend. Upon submission a confirmation will be sent to the email address provided.
| Date: | Monday, 8 October 2018 |
| Location: | Hotel |
| Address | |
| Address |
| 10:00 am - 11:00 am: | Brunch & Networking |
| 11:00 am - 11:10 am: | Welcome & JAX Overview |
| 11:10 am - 12:30 pm: | Scientific Presentations |
| 12:30 pm - 1:30 pm: | Lunch |
| 1:30 pm - 2:50 pm: | Scientific Presentations |
| 2:50 pm - 3:00 pm: | Closing Remarks |
| James Keck, Ph.D. | |
| Sr. Director, In Vivo Pharmacology & Clinical Lab Services | |
| The Jackson Laboratory | |
| Ralph Gareus, Ph. D. | |
| Director, Business Development - Europe | |
| The Jackson Laboratory |
Location:
Hilton Cambridge City Centre
20 Downing St, Cambridge CB2 3DT, UK
Speakers:
Ralph Gareus, Ph.D.
Director, Business Development in Europe
The Jackson Laboratory
Presenting Onco-Hu™: Humanized Mice for Evaluation of Immuno-Oncology Therapeutics
Jayesh Majithiya, M. Pharm, Ph. D.
Senior Scientist
Crescendo Biologics, Cambridge, UK
Presenting Humabody VH Therapeutics for Immuno Oncology
Richard Sainson, Ph.D.
Director Pharmacology and Translational Sciences
Kymab Ltd, Cambridge, UK
Presenting KY1044, a fully human anti-ICOS antibody, elicits long term in vivo anti-tumour efficacy as monotherapy and in combination with anti-PD-L1
Brian Soper, Ph.D.
Manager, Technical Information Services
The Jackson Laboratory, Bar Harbor, ME
Presenting Development of novel NSG mice to study human immunity
Location:
InterContinental Paris - Avenue Marceau
64 Avenue Marceau, 75008 Paris, France
Speakers:
Sophie Agaugue
R & D Manager
Celyad, Brussels, Belgium
Presenting Preclinical models to assess toxicity and efficacy of CAR-T cell therapies
Mike Brehm
Associate Professor
University of Massachusetts Medical School, Worcester, MA
Presenting Development of novel NSG mice to study human immunity
Nicolas Floch, Ph.D.
Associate Principal Scientist
AstraZeneca, Cambridge, UK
Presenting Improving the Predictive Value of Pre-clinical Work in Oncology Drug Discovery
Brian Soper, Ph.D.
Manager, Technical Information Services
The Jackson Laboratory, Bar Harbor, ME
Presenting Onco-Hu™: Humanized Mice for Evaluation of Immuno-Oncology Therapeutics
Location:
Kameha Grand Zürich
Dufaux-Strasse 1, 8152 Opfikon, Switzerland
Speakers:
Mike Brehm
Associate Professor
University of Massachusetts Medical School, Worcester, MA
Presenting Development of novel NSG mice to study human immunity
Johannes Sam
Group Leader In vivo models & Immunopharmacodynamics, Pharmacology
Roche Pharma Research & Early Development, Roche Innovation Center, Zürich, Switzerland
Presenting Humanized mouse models for drug discovery
Brian Soper
Manager, Technical Information Services
The Jackson Laboratory, Bar Harbor, ME
Presenting Onco-Hu™: Humanized Mice for Evaluation of Immuno-Oncology Therapeutics
Renata Stripecke
Director, Regenerative Immune Therapies Applied Laboratory
Associate Professor Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
Hannover Medical School, Hannover, Germany
Presenting T and B cell responses against herpes viruses and cancer studied in humanized mice
Location:
Heidelberg Marriott Hotel
Vangerowstraße 16, 69115 Heidelberg, Germany
Speakers:
Christian Buchholz
Head of Molecular Biotechnology and Gene Therapy
Paul-Ehrlich-Insitut, Langen, Germany
Presenting In vivo generation of CAR T cells in humanized mouse models
Ralph Gareus, Ph.D.
Director, Business Development in Europe
The Jackson Laboratory
Presenting Onco-Hu™: Humanized Mice for Evaluation of Immuno-Oncology Therapeutics
Brian Soper, Ph.D.
Manager, Technical Information Services
The Jackson Laboratory, Bar Harbor, ME
Presenting Development of novel NSG mice to study human immunity
Anja Wege, DVM, Ph.D.
Department of Gynecology and Obstetrics
University Hospital Regensburg, Regensburg, Germany
Presenting Humanized Tumor Mice- closing the gap between preclinical and clinical research